Skip to main content

Table 4 Association of PD-L1 staining with clinicopathologic factors in triple-negative patients with neoadjuvant chemotherapy

From: Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

 

TC

TCIC

IC

sTIL level

Factors

Negative

Positive

Fisher

Negative

Positive

Fisher

Negative

Positive

Fisher

Low

High

Fisher

N (%)

N (%)

P value

N (%)

N (%)

P value

N (%)

N (%)

P value

N (%)

N (%)

P value

Age

[N = 37]

 

[N = 34]

 

[N = 34]

 

[N = 37]

 

 < 50 years

14 (93)

1 (7)

0.0557

12 (80)

3 (20)

0.0171

13 (87)

2 (13)

0.064

10 (63)

6 (38)

0.5085

 ≥ 50 years

14 (64)

8 (36)

 

7 (37)

12 (63)

 

10 (53)

9 (47)

 

10 (48)

11 (52)

 

Race/ethnicity

[N = 37]

 

[N = 34]

 

[N = 34]

 

[N = 37]

 

 Black

2 (40)

3 (60)

0.1176

2 (40)

3 (60)

0.6382

3 (60)

2 (40)

0.4917

1 (25)

3 (75)

0.6123

 White+Latino

23 (82)

5 (18)

 

14 (56)

11 (44)

 

16 (64)

9 (36)

 

17 (59)

12 (41)

 

 Others

3 (75)

1 (25)

 

3 (75)

1 (25)

 

4 (100)

0 (0)

 

2 (50)

2 (50)

 

Histologic type

[N = 37]

 

[N = 34]

 

[N = 34]

 

[N = 37]

 

 IDC

26 (79)

7 (21)

0.2436

17 (57)

13 (43)

1

20 (67)

10 (33)

1

17 (52)

16 (48)

0.6088

 Metaplastic

2 (50)

2 (50)

 

2 (50)

2 (50)

 

3 (75)

1 (25)

 

3 (75)

1 (25)

 

Histologic gradea

[N = 37]

 

[N = 34]

 

[N = 34]

 

[N = 37]

 

 2

1 (100)

0 (0)

1

1 (100)

0 (0)

1

1 (100)

0 (0)

1

2 (67)

1 (33)

1

 3

27 (75)

9 (25)

 

18 (55)

15 (45)

 

22 (67)

11 (33)

 

18 (53)

16 (47)

 

sTIL level

[N = 35]

 

[N = 32]

 

[N = 32]

 

NA

  

 < 10%

16 (84)

3 (16)

0.2453

11 (61)

7 (39)

0.4765

12 (67)

6 (33)

1

   

 ≥ 10%

10 (63)

6 (38)

 

6 (43)

8 (57)

 

9 (64)

5 (36)

    

Tumor size

[N = 37]

 

[N = 34]

 

[N = 34]

 

[N = 37]

 

 ≤ 2 cm

9 (69)

4 (31)

0.796

6 (60)

4 (40)

0.8287

7 (70)

3 (30)

1

6 (43)

8 (57)

0.158

 > 2 to 5 cm

8 (80)

2 (20)

 

6 (60)

4 (40)

 

7 (70)

3 (30)

 

3 (38)

5 (63)

 

 > 5 cm

11 (79)

3 (21)

 

7 (50)

7 (50)

 

9 (64)

5 (36)

 

11 (73)

4 (27)

 

ypN

[N = 37]

 

[N = 34]

 

[N = 34]

 

[N = 37]

 

 (y)pN0

14 (74)

5 (26)

0.5435

11 (65)

6 (35)

0.4114

13 (76)

4 (24)

0.6365

11 (61)

7 (39)

0.1457

 (y)pN1

6 (86)

1 (14)

 

4 (67)

2 (33)

 

4 (67)

2 (33)

 

2 (25)

6 (75)

 

 (y)pN2

4 (57)

3 (43)

 

2 (29)

5 (71)

 

4 (57)

3 (43)

 

4 (50)

4 (50)

 

 (y)pN3

4 (100)

0 (0)

 

2 (50)

2 (50)

 

2 (50)

2 (50)

 

3 (100)

0 (0)

 

pM

[N = 37]

 

[N = 34]

 

[N = 34]

 

[N = 37]

 

 0

25 (74)

9 (26)

0.5622

18 (58)

13 (42)

0.5714

22 (71)

9 (29)

0.239

17 (50)

17 (50)

0.2342

 1

3 (100)

0 (0)

 

1 (33)

2 (67)

 

1 (33)

2 (67)

 

3 (100)

0 (0)

 

RCB category

[N = 37]

 

[N = 34]

 

[N = 34]

 

[N = 37]

 

 I

1 (50)

1 (50)

0.4578

0 (0)

1 (100)

0.059

0 (0)

1 (100)

0.0824

1 (50)

1 (50)

0.8668

 II

16 (80)

4 (20)

 

13 (72)

5 (28)

 

15 (83)

3 (17)

 

12 (57)

9 (43)

 

 III

11 (73)

4 (27)

 

6 (40)

9 (60)

 

8 (53)

7 (47)

 

7 (50)

7 (50)

 
  1. aHistologic grade for post-treatment tumors was based on pre-treatment grade
  2. IDC invasive ductal carcinoma, sTIL stromal tumor infiltrating lymphocytes, RCB residual cancer burden
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us